Senseonics (NYSE:SENS) Shares Down 4% - Time to Sell?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) shares fell 4% during mid-day trading on Friday . The company traded as low as $0.81 and last traded at $0.84. 7,077,628 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 24,212,734 shares. The stock had previously closed at $0.88.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SENS. StockNews.com began coverage on shares of Senseonics in a report on Thursday, December 26th. They issued a "sell" rating for the company. HC Wainwright reiterated a "buy" rating and issued a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

The stock's fifty day moving average price is $0.43 and its 200-day moving average price is $0.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm has a market cap of $504.78 million, a PE ratio of -6.52 and a beta of 0.64.

Insider Activity at Senseonics

In other Senseonics news, CFO Frederick T. Sullivan acquired 124,933 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $0.38 per share, with a total value of $47,474.54. Following the purchase, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. The trade was a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was acquired at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the purchase, the chief executive officer now owns 11,310,355 shares in the company, valued at $3,506,210.05. The trade was a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Senseonics

Several hedge funds have recently modified their holdings of SENS. Cubist Systematic Strategies LLC boosted its stake in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company's stock worth $166,000 after purchasing an additional 85,501 shares during the last quarter. Symmetry Partners LLC acquired a new stake in shares of Senseonics during the 3rd quarter worth about $164,000. GSA Capital Partners LLP acquired a new stake in shares of Senseonics during the 3rd quarter worth about $117,000. FMR LLC boosted its stake in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company's stock worth $59,000 after purchasing an additional 167,970 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company's stock worth $2,042,000 after purchasing an additional 179,103 shares during the last quarter. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.